# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hung-Teh Kao, Paul R. Hartig, and Theresa Branchek

Serial No.: Not Yet Known

Filed: Herewith

For: DNA ENCODING A HUMAN SEROTONIN (5-HT2) RECEPTOR

AND USES THEREOF

1185 Avenue of the Americas New York, New York 10036 August 14, 2001

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

### PRELIMINARY AMENDMENT AND INFORMATION DISCLOSURE STATEMENT

Please amend the subject application as follows:

# In the Specification:

On page 1, line 4, please insert the following paragraph:

This application is a continuation of U.S. Serial No. 09/145,864, filed September 2, 1998, now allowed, a divisional of U.S. Serial No. 08/613,044, filed March 8, 1996, now U.S. Patent No. 5,885,785, issued March 23, 1999, a divisional of U.S. Serial No. 08/347,591, filed November 30, 1994, now U.S. Patent No. 5,661,024, issued August 26, 1997, a continuation of Serial No. 08/232,325, filed April 25, 1994, now abandoned, a continuation of Serial No. 07/999,661, filed December 29, 1992, now abandoned, a continuation of 07/635,402, filed December 31, 1990, now abandoned, a continuation of Serial No. 07/429,832, filed October 31, 1989, now abandoned, the contents of which are

Hung-Teh Kao, et al.

Serial No.: Not Yet Known

Filed: Herewith

Page 2

hereby incorporated by reference into the subject application. --

### In the Claims:

Please cancel claims 4-43, 46, and 49-51 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

#### REMARKS

Claims 1 to 51 were pending in the subject application. By this Amendment, applicants have canceled claims 4-43, 46, and 49-51 without prejudice or disclaimer. Accordingly, upon entry of this Amendment, claims 1, 2, 3, 44, 45, 47 and 48 will be pending and under examination.

## Information Disclosure Statement

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (EXHIBIT 1). The following references were previously cited in connection with the prosecution of U.S. Serial Number 09/145,864 from which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

1. U.S. Patent No. 4,985,352, issued January 15, 1991, Julius, et al:

- U.S. Patent No. 5,155,218, issued October 13, 1992, Weinshank, et al.;
- 3. U.S. Patent No. 5,360,735, issued November 1, 1994, Weinshank, et al.;
- 4. U.S. Patent No. 5,472,866, issued December 5, 1995, Gerald, et al.;
- U.S. Patent No. 5,476,782, issued December 19, 1995,
   Weinshank, et al.;
- 6. U.S. Patent No. 5,661,024, issued August 26, 1997, Kao et al.;
- 7. U.S. Patent No. 5,885,785; issued March 23, 1999, Kao et al.;
- 8. European Patent Application EP 0 565 370, published October 13, 1993;
- 9. French Patent Application No. 2696749, published April 15, 1994;
- 10. PCT International Patent Publication No. 95/06117, published March 2, 1995;
- 11. Kramer, R.A., et al., "Regulated Expression of a Human Interferon Gene in Yeast, Control by Phosphate Concentration or Temperature," PNAS 81: 367-370 (1984);
- 12. Cory, R.N., et al., "5-HT $_2$  Receptor-Stimulated Inositol

Hung-Teh Kao, et al.

Serial No.: Not Yet Known

Filed: Herewith

Page 4

Phosphate Formation in Rat Aortic Myocyte," Euro. J. Pharm. 131: 153-157 (1986);


- 13. Hoyer, D., et al, "Serotonin Receptors in the Human Brain. II. Characterization and Autoradiographic Localization of 5-HT<sub>1C</sub> and 5-HT<sub>2</sub> Recognition Sites," Brain Research <u>376</u>: 97-107 (1986);
- 14. Lyon, R.A., et al, "<sup>3</sup>H-DOB (4-Bromo-2, 5-Dimethoxyphenylisopropylamine) Labels Guanyl Nucleotide-Sensitive State of Cortical 5-HT<sub>2</sub> Receptors," *Mol. Pharm.*31: 194-199 (1986);
- 15. Cory, R.N., et al, "The 5-Hydroxytryptamine (5-HT<sub>2</sub>) Receptor Stimulates Inositol Phosphate Formation in Intact and Broken WRK1 Cells: Determination of Occupancy-Response Relationships for 5-HT Agonists," J.Pharm. Exp. Ther.

  241(1): 258-267 (1987);
- 16. Shenker, A., et al., "Pharmacological Characterization of Two 5-Hydroxytryptamine Receptors Coupled to Adenylate Cyclase in Guinea Pig Hippocampal Membranes," Mol. Pharm.

  31(4): 357-367 (1987);
- 17. Lubbert, H., et al., "cDNA Cloning of a Serotonin 5-HT $_{1C}$  Receptor by Electrophysiological Assays of mRNA-Injected Xenopus Oocyte," PNAS <u>84</u>: 4332-4336 (1987);
- 18. Kobilka, B.K., et al., "An Intronless Gene Encoding a Potential Member of the Family of Receptors Coupled To Guanine Nucleotide Regulatory Proteins," Nature 329: 75-79 (1987);

- 19. Marzoni, G., et al., "6-Methylergoline-8-Carboxylic Acid
  Esters as Serotonin Antagonists: N¹-Substituent Effects of
  5HT<sub>2</sub> Receptor Affinity," J.Med. Chem. 30(10): 1823-1826
  (1987);
- 20. Kaufman, R.J., et al., "High Level Production of Proteins in Mammalian Cells," Genetic Engineering 9: 155-198 (1987);
- 21. Stevens, et al., "Channel Families in the Brain," *Nature*328: 198-199 (1987);
- 22. Fargin, A., et al., "The Genomic Clone G-21 Which Resembles a  $\beta$ -Adrenergic Receptor Sequence Encodes the 5-HT1A Receptor," Nature 335: 358-360 (1988);
- 23. Harris, T.J., et al., "Expression Of Eukaryotic Genes in E.Coli," Genetic Engineering (1988) 4: 127-141;
- 24. Julius, D., et al., "Molecular Characterization of a Functional cDNA Encoding the Serotonin 1c Receptor," Science

  241: 558-564 (1988);
- 25. Pritchett, D.B., et al., "Structure and Functional Expression of Cloned Rat Serotonin 5HT-2 Receptor," EMBO J. 7: 4135-4140 (1988);
- 26. Pierce, P., et al., "Evidence for Distinct 5-Hydroxytryptamine<sub>2</sub> Binding Site Subtypes in Cortical Membrane Preparations," J. Neurochem. <u>52</u>: 656-658 (1989);
- 27. Amstien, R., et al., "Platelet Deactivation by 5HT2-Receptor Blockade Parallels the antihypertensive Response to Ketanserin," J. Hypertense. 7(4): 255-260 (1989);



- 28. Wright, D.E., et al, "5-Carboxamidotryptamine Elicits 5-HT<sub>2</sub> and 5-HT<sub>3</sub> Receptor-Mediated Cardiovascular Responses in the Conscious Rabbit: Evidence for 5-HT Release from Platelets," Cardiovasc. Pharm. 13(4): 557-564 (1989);
- 29. Strader, C.D., et al, "Structural Basis of  $\beta$ -Adrenergic Receptor Function, FASEB J. 3: 1825-1832 (1989);
- 30. Schmidt, A.W., et al, "5-Hydroxytryptamine Receptor Families," FASEB J. 3: 2242-2250 (1989);
- 31. Cohen, M.L., et al., "Lack of a Difference Between Ketanserin and Ritanserin In Central v. Peripheral Serotonin Receptor Antagonism," Life Sci. 45(13): 1185-1189 (1989);
- 32. Cohen M.L., et al., "Effect of LY53857, A Selective 5HT<sub>2</sub>
  Receptor Antagonist on 5HT-Induced Increases in Cutaneous
  Vascular Permeability in Rats," Life Sci. 44(14): 957-961
  (1989);
- 33. Baez, M., et al., "Pharmacological and Molecular Evidence that the Contractile Response to Serotonin in Rat Stomach Fundus is Not Mediated by Activation of the 5-Hydroxytryptamine<sub>1C</sub> Receptor," Mol. Pharm. 38(1): 31-37 (1990);
- 34. Branchek, T., et al., "[3H]-DOB(4-Bromo-2, 5-Dimethoxyphenylisopropylamine) and [3H] Ketanserin Label Two Affinity State of the Cloned Human 5-Hydroxytrptamine<sub>2</sub> Receptor," Mol. Pharm. 38: 604-609 (1990);
- 35. Hartig, P., et al., "The Molecular Biology of Serotonin

Receptors," Neuropsychopharmacology 3(5/6): 335-347 (1990);

- 36. Julius, D., et al., "Distinct by Functionally Conserved Serotonin Receptors," PNAS 87: 928-932 (1990);
- 37. Saltzman, A.G., et al, "Cloning of the Human Serotoini 5-HT2 and 5HT1C Receptor Subtypes," Biochem. Biophys. Res. Comm. 181(3): 1469-1478 (1991);
- 38. Kao, H.T., et al, "Site-Directed Mutagenesis of a Single Residue Changes the Binding Properties of the Serotonin 5-HT2 Receptor from a Human to a Rate Pharmacology," FEBS Letters 307(3): 324-328 (1992);
- 39. Mita et al., "Evidence for the presence of D2 and 5-HT2 receptors in the human prefrontal cortex," Jap. J. Pharmacol. 32: 1027-1032 (1982);
- 40. Bowie, J.U., et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," Science 247: 1306-1310 (1990);
- 41. Wells, J.A., "Additivity of Mutational Effects in Proteins," Biochemistry 29(37): 8509-8517 (1990); and
- 42. Ngo, J.T., et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," In: The Protein Folding Problem and Tertiary Structure Prediction, pp 492-495 (1994) Merz, K. Jr. and LeGrand, S. (Eds), Birkhauser (Boston).

If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed \$710.00 fee for filing the subject application, is deemed necessary in connection with the filing of this Preliminary Amendment and Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

Alan J. Morrison Registration No. 37,399 Attorney for Applicants Cooper & Dunham LLP 1185 Ave of the Americas New York, New York 10036 (212) 278-0400